Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

The Optimal Radiation Dose to Induce Robust Systemic Anti-Tumor Immunity.

Poleszczuk J, Enderling H.

Int J Mol Sci. 2018 Oct 29;19(11). pii: E3377. doi: 10.3390/ijms19113377.

2.

Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy.

Walker R, Poleszczuk J, Pilon-Thomas S, Kim S, Anderson AARA, Czerniecki BJ, Harrison LB, Moros EG, Enderling H.

Sci Rep. 2018 Jun 21;8(1):9474. doi: 10.1038/s41598-018-27718-1.

3.

Evaluating the potential for maximized T cell redistribution entropy to improve abscopal responses to radiotherapy.

Walker R, Schoenfeld JD, Pilon-Thomas S, Poleszczuk J, Enderling H.

Converg Sci Phys Oncol. 2017 Sep;3(3). pii: 034001. doi: 10.1088/2057-1739/aa7269. Epub 2017 Jun 15.

4.

Toward early detection of Helicobacter pylori-associated gastric cancer.

Walker R, Poleszczuk J, Mejia J, Lee JK, Pimiento JM, Malafa M, Giuliano AR, Enderling H, Coppola D.

Gastric Cancer. 2018 Mar;21(2):196-203. doi: 10.1007/s10120-017-0748-z. Epub 2017 Jul 19.

PMID:
28725964
5.

Predicting Patient-Specific Radiotherapy Protocols Based on Mathematical Model Choice for Proliferation Saturation Index.

Poleszczuk J, Walker R, Moros EG, Latifi K, Caudell JJ, Enderling H.

Bull Math Biol. 2018 May;80(5):1195-1206. doi: 10.1007/s11538-017-0279-0. Epub 2017 Jul 5.

PMID:
28681150
6.

Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival.

Poleszczuk J, Luddy K, Chen L, Lee JK, Harrison LB, Czerniecki BJ, Soliman H, Enderling H.

Breast Cancer Res. 2017 Jun 30;19(1):75. doi: 10.1186/s13058-017-0870-1.

7.

Stratifying prostate cancer patients by relative lymph node involvement: population- and modeling-based study.

Poleszczuk JT, Johnstone PA, Enderling H.

Cancer Med. 2016 Aug;5(8):1850-5. doi: 10.1002/cam4.776. Epub 2016 May 26.

8.

Agent-Based Modeling of Cancer Stem Cell Driven Solid Tumor Growth.

Poleszczuk J, Macklin P, Enderling H.

Methods Mol Biol. 2016;1516:335-346. doi: 10.1007/7651_2016_346.

PMID:
27044046
9.

Cancer Stem Cell Plasticity as Tumor Growth Promoter and Catalyst of Population Collapse.

Poleszczuk J, Enderling H.

Stem Cells Int. 2016;2016:3923527. doi: 10.1155/2016/3923527. Epub 2015 Dec 8.

10.

Abscopal Benefits of Localized Radiotherapy Depend on Activated T-cell Trafficking and Distribution between Metastatic Lesions.

Poleszczuk JT, Luddy KA, Prokopiou S, Robertson-Tessi M, Moros EG, Fishman M, Djeu JY, Finkelstein SE, Enderling H.

Cancer Res. 2016 Mar 1;76(5):1009-18. doi: 10.1158/0008-5472.CAN-15-1423. Epub 2016 Feb 1.

11.

A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation.

Prokopiou S, Moros EG, Poleszczuk J, Caudell J, Torres-Roca JF, Latifi K, Lee JK, Myerson R, Harrison LB, Enderling H.

Radiat Oncol. 2015 Jul 31;10:159. doi: 10.1186/s13014-015-0465-x.

12.

Therapeutic implications from sensitivity analysis of tumor angiogenesis models.

Poleszczuk J, Hahnfeldt P, Enderling H.

PLoS One. 2015 Mar 18;10(3):e0120007. doi: 10.1371/journal.pone.0120007. eCollection 2015.

13.

Evolution and phenotypic selection of cancer stem cells.

Poleszczuk J, Hahnfeldt P, Enderling H.

PLoS Comput Biol. 2015 Mar 5;11(3):e1004025. doi: 10.1371/journal.pcbi.1004025. eCollection 2015 Mar.

14.

A High-Performance Cellular Automaton Model of Tumor Growth with Dynamically Growing Domains.

Poleszczuk J, Enderling H.

Appl Math (Irvine). 2014 Jan;5(1):144-152.

15.

Biphasic modulation of cancer stem cell-driven solid tumour dynamics in response to reactivated replicative senescence.

Poleszczuk J, Hahnfeldt P, Enderling H.

Cell Prolif. 2014 Jun;47(3):267-76. doi: 10.1111/cpr.12101. Epub 2014 Mar 25.

PMID:
24666838

Supplemental Content

Loading ...
Support Center